Drug Delivery

Serving the Drug Delivery and Formulation Ecosystem

Lead Editorial

How Genentech Makes Device Decisions to De-Risk Combination Product Development

Genentech Senior Director, Josh Horvath, discusses the framework he uses to de-risk combination product development by utilizing off-the-shelf devices, calculating for sustainability and improving collaboration between device and formulation teams.

Novel Approaches to Achieve Long-Acting Formulations for Biologics

Investing in More Engaging Connected Devices to Improve Patient Outcomes

Working with Outsourcers to Get Combination Products to Market Faster

PODD 2023: The Future of Digital Technology in the Connected Device Space

Editorial

New Processes Enabling the Development and Commercialization of Long-Acting Injectables

Partnering Advice from the Eli Lilly Genetic Medicines Search & Evaluate Team Lead

Bringing the User Experience to Drug Delivery Devices – An Untapped Opportunity For Pharma

Exosome Delivery: The Past and Future

How Chiesi Evaluates Cell & Gene Delivery Technologies

How Pfizer is Improving Lipid Nanoparticle Delivery of Complex Therapies

How AstraZeneca is Solving Delivery Challenges for mRNA Therapies

Developing a Novel Oral Monoclonal Antibody

Product Drug Delivery Optimization for More Choices in Flexible Care Settings with Roche

Drug Delivery Patient Perspective on Self-Injection, Plus Areas for Improvement

From the Langer Lab: Self-Boosting Vaccines and the Power of Collaboration

How Subcutaneous Delivery of Checkpoint Inhibitors Enabled a Remote Oncology Trial at USC

A Drug Delivery Veteran on Finding External Technologies and Forming Successful Partnerships

Genentech R&D VP on Optimizing Drug Delivery for a Complex Portfolio

Biological Engineering MIT Professor on Solving Unmet Medical Needs and Increasing Gender Equity in Biotech

AstraZeneca’s Head of Advanced Drug Delivery Discusses Her Career Journey and Passion for the Industry

Serving the Drug Delivery and Formulation Ecosystem

Lead Editorial

How Genentech Makes Device Decisions to De-Risk Combination Product Development

Featured Editorial

Novel Approaches to Achieve Long-Acting Formulations for Biologics

Investing in More Engaging Connected Devices to Improve Patient Outcomes

Working with Outsourcers to Get Combination Products to Market Faster

PODD 2023: The Future of Digital Technology in the Connected Device Space

More Related Content

Editorial

New Processes Enabling the Development and Commercialization of Long-Acting Injectables

Partnering Advice from the Eli Lilly Genetic Medicines Search & Evaluate Team Lead

Bringing the User Experience to Drug Delivery Devices – An Untapped Opportunity For Pharma

Exosome Delivery: The Past and Future

How Chiesi Evaluates Cell & Gene Delivery Technologies

How Pfizer is Improving Lipid Nanoparticle Delivery of Complex Therapies

How AstraZeneca is Solving Delivery Challenges for mRNA Therapies

Developing a Novel Oral Monoclonal Antibody

Product Drug Delivery Optimization for More Choices in Flexible Care Settings with Roche

Drug Delivery Patient Perspective on Self-Injection, Plus Areas for Improvement

From the Langer Lab: Self-Boosting Vaccines and the Power of Collaboration

How Subcutaneous Delivery of Checkpoint Inhibitors Enabled a Remote Oncology Trial at USC

A Drug Delivery Veteran on Finding External Technologies and Forming Successful Partnerships

Genentech R&D VP on Optimizing Drug Delivery for a Complex Portfolio

Biological Engineering MIT Professor on Solving Unmet Medical Needs and Increasing Gender Equity in Biotech

AstraZeneca’s Head of Advanced Drug Delivery Discusses Her Career Journey and Passion for the Industry

Subscribe for More Information

Search By Type:

Search By Category:

Search Within Date Range:

Serving the Drug Delivery and Formulation Ecosystem

Lead Editorial

How Genentech Makes Device Decisions to De-Risk Combination Product Development

Featured Editorial

Novel Approaches to Achieve Long-Acting Formulations for Biologics

Investing in More Engaging Connected Devices to Improve Patient Outcomes

Working with Outsourcers to Get Combination Products to Market Faster

PODD 2023: The Future of Digital Technology in the Connected Device Space

More Related Content

Editorial

New Processes Enabling the Development and Commercialization of Long-Acting Injectables

Partnering Advice from the Eli Lilly Genetic Medicines Search & Evaluate Team Lead

Bringing the User Experience to Drug Delivery Devices – An Untapped Opportunity For Pharma

Exosome Delivery: The Past and Future

How Chiesi Evaluates Cell & Gene Delivery Technologies

How Pfizer is Improving Lipid Nanoparticle Delivery of Complex Therapies

How AstraZeneca is Solving Delivery Challenges for mRNA Therapies

Developing a Novel Oral Monoclonal Antibody

Product Drug Delivery Optimization for More Choices in Flexible Care Settings with Roche

Drug Delivery Patient Perspective on Self-Injection, Plus Areas for Improvement

From the Langer Lab: Self-Boosting Vaccines and the Power of Collaboration

How Subcutaneous Delivery of Checkpoint Inhibitors Enabled a Remote Oncology Trial at USC

A Drug Delivery Veteran on Finding External Technologies and Forming Successful Partnerships

Genentech R&D VP on Optimizing Drug Delivery for a Complex Portfolio

Biological Engineering MIT Professor on Solving Unmet Medical Needs and Increasing Gender Equity in Biotech

AstraZeneca’s Head of Advanced Drug Delivery Discusses Her Career Journey and Passion for the Industry

Subscribe for More Information